Zielinski G Denise, Snijders Peter J F, Rozendaal Lawrence, Daalmeijer Nathalie Fransen, Risse Elle K J, Voorhorst Feja J, Jiwa N Medi, van der Linden Hans C, de Schipper Frits A, Runsink Arnold P, Meijer Chris J L M
Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
J Pathol. 2003 Dec;201(4):535-43. doi: 10.1002/path.1480.
Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population-based screening programmes. Adding high-risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix. Archival formalin-fixed specimens of indisputable ACIS (n=65) and AdCA (n=77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR-enzyme immunoassay (EIA) and type-specific E7 PCR for 14 hrHPV types. Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV-positive. HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs. Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV-positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p<0.001). Immunostaining for p53, pointing to stabilized wild-type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p=0.01). No difference in p16INK4a and p53 immunostaining was found between hrHPV-negative cervical AdCAs and endometrial AdCAs. Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV. Since all ACISs and nearly all cervical AdCAs were hrHPV-positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA.
在基于人群的筛查项目中,宫颈原位腺癌(ACIS)和腺癌(AdCA)常常被漏诊。在宫颈癌筛查中增加高危型人乳头瘤病毒(hrHPV)检测可能会提高ACIS和AdCA的检出率。由于可归因于hrHPV感染的宫颈AdCA的确切比例仍存在争议,因此对宫颈ACIS和AdCA中的hrHPV存在情况进行了一项全面研究。通过GP5+/6+ PCR酶免疫测定(EIA)和针对14种hrHPV类型的型特异性E7 PCR,对存档的经福尔马林固定的无可争议的宫颈ACIS(n = 65)和AdCA(n = 77)标本进行hrHPV DNA检测。进一步进行p16INK4A和p53免疫染色,以评估可能与HPV无关的替代致癌途径。在所有(100%)ACIS和72例(94%)宫颈AdCA中发现了hrHPV DNA,而20例子宫内膜AdCA均未检测出hrHPV阳性。HPV 18最为常见,在68%的ACIS和55%的宫颈AdCA中呈单一或多重感染。作为hrHPV E7功能潜在标志物的p16INK4a弥漫性免疫染色在hrHPV阳性的宫颈AdCA(19/20;95%)中比在无hrHPV的宫颈AdCA(1/5;20%;p<0.001)中更为常见。针对p53的免疫染色表明野生型或突变型p53蛋白稳定,在hrHPV阴性的宫颈AdCA中更为常见(p = 0.01)。在hrHPV阴性的宫颈AdCA和子宫内膜AdCA之间,未发现p16INK4a和p53免疫染色有差异。因此,只有少数宫颈AdCA显示无HPV DNA且免疫染色谱提示病因与HPV无关。由于所有ACIS和几乎所有宫颈AdCA均为hrHPV阳性,在宫颈癌筛查项目中纳入hrHPV检测可能会显著降低宫颈AdCA的发病率。